I
Iowa Approach
Growing Innovation & transforming the practice of medicine
About Iowa Approach
Iowa Approach Inc., which was subsequently rebranded as Farapulse, Inc., represents a significant development in the field of cardiac electrophysiology. The company was established in 2012 by Dr. Steven Mickelsen, an assistant professor and clinical cardiac electrophysiologist at the University of Iowa. Drawing on more than a decade of direct experience within cardiac catheterization labs, Dr. Mickelsen identified critical limitations in existing treatments for atrial fibrillation (AFib), the world's most common heart rhythm disorder. This firsthand insight drove him to invent and prototype a novel medical device system to make AFib ablation safer, faster, and more accessible.
The company's core business revolves around its Pulsed Field Ablation (PFA) system. This technology addresses a market where an estimated 59 million people globally suffer from AFib, a condition that increases the risk of stroke and carries a significant healthcare cost burden. The business model focused on the development and commercialization of this proprietary medical device. Unlike traditional thermal ablation methods that use extreme heat or cold to destroy problematic heart tissue and risk damaging surrounding structures, the Farapulse PFA system utilizes non-thermal, tissue-selective electric fields. This method allows for the precise ablation of cardiac tissue responsible for irregular heartbeats while preserving adjacent healthy tissue, such as the esophagus or phrenic nerve. The primary clients for this technology are hospitals and cardiac electrophysiologists who perform ablation procedures.
The Farapulse system, consisting of a specialized catheter and an energy generator, demonstrated a substantial improvement in safety and procedural efficiency. Clinical data and real-world use have shown a high rate of effectiveness with no reported instances of common complications like esophageal injury or pulmonary vein stenosis. The journey from concept to market was supported by the University of Iowa Research Foundation, and the company attracted early investment from Boston Scientific in 2014. This strategic relationship culminated in June 2021, when Boston Scientific exercised its option to fully acquire Farapulse, Inc. The acquisition involved an upfront payment of approximately $295 million for the remaining stake, plus potential milestone and revenue-based payments. The system received FDA approval for treating paroxysmal AFib in January 2024 and expanded approval for persistent AFib in July 2025, solidifying its position within the Boston Scientific electrophysiology portfolio.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Menlo Park, United States
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 59.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Aug 2018 | $12M | $48M | Undisclosed | — |
| DEBT✓Debt | Jul 2017 | $5M | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Iowa Approach is 110 monthly website visits. Iowa Approach's team declined 22.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Iowa Approach in the Menlo Park ecosystem
The Iowa Approach office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Sante Ventures
Other known investors1 additional known investor
University of Iowa
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Iowa Approach on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Iowa Approach’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










